Detalhe da pesquisa
1.
The T-Cell Growth Factor Interleukin-2, Which Is Occasionally Targeted by Autoantibodies, Qualifies as Drug for the Treatment of Allergy, Autoimmunity, and Cancer: Collegium Internationale Allergologicum (CIA) Update 2024.
Int Arch Allergy Immunol
; 185(3): 286-300, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38086339
2.
Flow Cytometry-Based Measurement of Antibodies Specific for Cell Surface-Expressed Folded SARS-CoV-2 Receptor-Binding Domains.
Vaccines (Basel)
; 12(4)2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38675759